This pipeline uses various statistical tests to identify miRs whose log2 expression levels correlated to selected clinical features.
Testing the association between 469 miRs and 10 clinical features across 66 samples, statistically thresholded by P value < 0.05 and Q value < 0.3, 5 clinical features related to at least one miRs.
-
2 miRs correlated to 'NEOPLASM.DISEASESTAGE'.
-
HSA-MIR-10A , HSA-MIR-181B-1
-
4 miRs correlated to 'PATHOLOGY.T.STAGE'.
-
HSA-MIR-181B-1 , HSA-MIR-181A-1 , HSA-MIR-200A , HSA-MIR-429
-
1 miR correlated to 'GENDER'.
-
HSA-MIR-219-1
-
2 miRs correlated to 'KARNOFSKY.PERFORMANCE.SCORE'.
-
HSA-MIR-7-1 , HSA-MIR-181D
-
1 miR correlated to 'RACE'.
-
HSA-MIR-410
-
No miRs correlated to 'AGE', 'PATHOLOGY.N.STAGE', 'PATHOLOGY.M.STAGE', 'NUMBERPACKYEARSSMOKED', and 'ETHNICITY'.
Complete statistical result table is provided in Supplement Table 1
Table 1. Get Full Table This table shows the clinical features, statistical methods used, and the number of miRs that are significantly associated with each clinical feature at P value < 0.05 and Q value < 0.3.
Clinical feature | Statistical test | Significant miRs | Associated with | Associated with | ||
---|---|---|---|---|---|---|
AGE | Spearman correlation test | N=0 | ||||
NEOPLASM DISEASESTAGE | Kruskal-Wallis test | N=2 | ||||
PATHOLOGY T STAGE | Spearman correlation test | N=4 | higher stage | N=2 | lower stage | N=2 |
PATHOLOGY N STAGE | Spearman correlation test | N=0 | ||||
PATHOLOGY M STAGE | Kruskal-Wallis test | N=0 | ||||
GENDER | Wilcoxon test | N=1 | male | N=1 | female | N=0 |
KARNOFSKY PERFORMANCE SCORE | Spearman correlation test | N=2 | higher score | N=1 | lower score | N=1 |
NUMBERPACKYEARSSMOKED | Spearman correlation test | N=0 | ||||
RACE | Kruskal-Wallis test | N=1 | ||||
ETHNICITY | Wilcoxon test | N=0 |
Table S1. Basic characteristics of clinical feature: 'AGE'
AGE | Mean (SD) | 51.52 (14) |
Significant markers | N = 0 |
Table S2. Basic characteristics of clinical feature: 'NEOPLASM.DISEASESTAGE'
NEOPLASM.DISEASESTAGE | Labels | N |
STAGE I | 21 | |
STAGE II | 25 | |
STAGE III | 14 | |
STAGE IV | 6 | |
Significant markers | N = 2 |
Table S3. Get Full Table List of 2 miRs differentially expressed by 'NEOPLASM.DISEASESTAGE'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-10A | 0.0004293 | 0.201 |
HSA-MIR-181B-1 | 0.0004795 | 0.224 |
Table S4. Basic characteristics of clinical feature: 'PATHOLOGY.T.STAGE'
PATHOLOGY.T.STAGE | Mean (SD) | 2.02 (0.85) |
N | ||
1 | 21 | |
2 | 25 | |
3 | 18 | |
4 | 2 | |
Significant markers | N = 4 | |
pos. correlated | 2 | |
neg. correlated | 2 |
Table S5. Get Full Table List of 4 miRs significantly correlated to 'PATHOLOGY.T.STAGE' by Spearman correlation test
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-181B-1 | 0.505 | 1.53e-05 | 0.00717 |
HSA-MIR-181A-1 | 0.445 | 0.0001813 | 0.0848 |
HSA-MIR-200A | -0.4362 | 0.0002511 | 0.117 |
HSA-MIR-429 | -0.4218 | 0.0004198 | 0.196 |
Table S6. Basic characteristics of clinical feature: 'PATHOLOGY.N.STAGE'
PATHOLOGY.N.STAGE | Mean (SD) | 0.16 (0.47) |
N | ||
0 | 40 | |
1 | 3 | |
2 | 2 | |
Significant markers | N = 0 |
Table S7. Basic characteristics of clinical feature: 'PATHOLOGY.M.STAGE'
PATHOLOGY.M.STAGE | Labels | N |
M0 | 34 | |
M1 | 2 | |
MX | 9 | |
Significant markers | N = 0 |
Table S8. Basic characteristics of clinical feature: 'GENDER'
GENDER | Labels | N |
FEMALE | 27 | |
MALE | 39 | |
Significant markers | N = 1 | |
Higher in MALE | 1 | |
Higher in FEMALE | 0 |
Table S9. Get Full Table List of one miR differentially expressed by 'GENDER'. 0 significant gene(s) located in sex chromosomes is(are) filtered out.
W(pos if higher in 'MALE') | wilcoxontestP | Q | AUC | |
---|---|---|---|---|
HSA-MIR-219-1 | 638 | 0.0005136 | 0.241 | 0.7705 |
2 miRs related to 'KARNOFSKY.PERFORMANCE.SCORE'.
Table S10. Basic characteristics of clinical feature: 'KARNOFSKY.PERFORMANCE.SCORE'
KARNOFSKY.PERFORMANCE.SCORE | Mean (SD) | 89.09 (9.4) |
Score | N | |
70 | 1 | |
80 | 2 | |
90 | 5 | |
100 | 3 | |
Significant markers | N = 2 | |
pos. correlated | 1 | |
neg. correlated | 1 |
Table S11. Get Full Table List of 2 miRs significantly correlated to 'KARNOFSKY.PERFORMANCE.SCORE' by Spearman correlation test
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-7-1 | 0.9028 | 0.0001411 | 0.0645 |
HSA-MIR-181D | -0.8642 | 0.0006005 | 0.274 |
Table S12. Basic characteristics of clinical feature: 'NUMBERPACKYEARSSMOKED'
NUMBERPACKYEARSSMOKED | Mean (SD) | 25.09 (22) |
Significant markers | N = 0 |
Table S13. Basic characteristics of clinical feature: 'RACE'
RACE | Labels | N |
ASIAN | 2 | |
BLACK OR AFRICAN AMERICAN | 4 | |
WHITE | 58 | |
Significant markers | N = 1 |
Table S14. Get Full Table List of one miR differentially expressed by 'RACE'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-410 | 0.0004995 | 0.229 |
-
Expresson data file = KICH-TP.miRseq_RPKM_log2.txt
-
Clinical data file = KICH-TP.merged_data.txt
-
Number of patients = 66
-
Number of miRs = 469
-
Number of clinical features = 10
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.